FeesSafety
Pluang+

Omeros faces securities fraud probe after EMA rejects drug approval twice, stock plunges.

Market News
29 Oct 2026, 16:50 WIB
PRNewsWire
View Source
Bearish
Omeros faces securities fraud probe after EMA rejects drug approval twice, stock plunges.

Pomerantz LLP is investigating Omeros Corporation for potential securities fraud following two negative opinions from the European Medicines Agency (EMA) on its drug narsoplimab for treating TA-TMA. The EMA's initial rejection in June 2026 caused Omeros's stock to drop 19.12%, and a subsequent rejection in October led to a further 13.78% decline. This legal probe could impact investor confidence and the company's future regulatory efforts. Investors are advised to contact Pomerantz LLP for more information on joining the class action lawsuit.

Regarding the investigation into Omeros Corporation, here is Pluang's snapshot of the health sector as of Oct 29, 2026 20:51 WIB: Out of 150 priced US health stocks, 126 rose and 24 fell today. Notable movers include Eli Lilly And Co (LLY) at USD 1,387.98 with a 7.70% increase and a Pluang order activity of 29% Sell / 71% Buy, ClearPoint Neuro Inc (CLPT) at USD 11.20 up 6.06% with balanced order activity, and Baxter International Inc (BAX) at USD 24.09 down 5.38%.

More News

Philippines solar market to hit 23.35 GW by 2032, growing at 27.46% CAGR driven by cheaper costs and corporate demand

Philippines solar market to hit 23.35 GW by 2032, growing at 27.46% CAGR driven by cheaper costs and corporate demand

The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...

Market News
Bullish
33 minutes ago
Equinor shares trade ex-dividend for Q2 2026 with a $0.39 payout starting Nov 13.

Equinor shares trade ex-dividend for Q2 2026 with a $0.39 payout starting Nov 13.

Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...

Company Fundamentals
Neutral
44 minutes ago
China Eastern Airlines signs $540M procurement deals, unveils new aviation tech at CIIE

China Eastern Airlines signs $540M procurement deals, unveils new aviation tech at CIIE

China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...

Bullish
1 hour ago
Eramet launches €500M share capital increase with preferential subscription rights to reduce debt.

Eramet launches €500M share capital increase with preferential subscription rights to reduce debt.

Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...

Company Fundamentals
Neutral
3 hours ago
PAS-004 shows strong reductions in neurofibroma size with good safety, advancing to Phase 2 trials after FDA clearance.

PAS-004 shows strong reductions in neurofibroma size with good safety, advancing to Phase 2 trials after FDA clearance.

Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App